Gainers

• Catheter Precision (AMEX:VTAK) shares moved upwards by 69.3% to $2.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 million.
• MiNK Therapeutics (NASDAQ:INKT) stock rose 54.44% to $16.14. The company's market cap stands at $49.0 million.
• BioRestorative Therapies (NASDAQ:BRTX) shares rose 36.55% to $0.32. The market value of their outstanding shares is at $5.0 million.
• Zevra Therapeutics (NASDAQ:ZVRA) stock moved upwards by 16.55% to $10.63. The company's market cap stands at $513.4 million. As per the news, the Q4 earnings report came out yesterday.
• HeartBeam (NASDAQ:BEAT) stock moved upwards by 16.21% to $1.72. The company's market cap stands at $50.9 million.
• ENDRA Life Sciences (NASDAQ:NDRA) stock moved upwards by 15.86% to $3.96. The market value of their outstanding shares is at $3.9 million.

Losers

• Pomdoctor (NASDAQ:POM) shares declined by 20.2% to $0.35 during Tuesday's pre-market session. The company's market cap stands at $52.0 million.
• BioNTech (NASDAQ:BNTX) stock decreased by 16.27% to $85.54. The company's market cap stands at $24.5 billion. As per the news, the Q4 earnings report came out today.
• AquaBounty Techs (NASDAQ:AQB) stock decreased by 13.96% to $0.77. The market value of their outstanding shares is at $3.4 million.
• Evotec (NASDAQ:EVO) shares fell 13.87% to $2.61. The market value of their outstanding shares is at $1.0 billion.
• BioAtla (NASDAQ:BCAB) stock decreased by 9.84% to $0.17. The company's market cap stands at $14.0 million.
• Spectral AI (NASDAQ:MDAI) stock fell 7.81% to $1.3. The market value of their outstanding shares is at $43.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.